With 0.51 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.62 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $14.54 whereas the lowest price it dropped to was $13.57. The 52-week range on ZYME shows that it touched its highest point at $17.70 and its lowest point at $7.97 during that stretch. It currently has a 1-year price target of $18.19. Beta for the stock currently stands at 1.12.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZYME was down-trending over the past week, with a drop of -7.15%, but this was up by 10.60% over a month. Three-month performance surged to 23.83% while six-month performance rose 63.88%. The stock gained 71.34% in the past year, while it has gained 37.54% so far this year. A look at the trailing 12-month EPS for ZYME yields -1.51 with Next year EPS estimates of -1.52. For the next quarter, that number is -0.12. This implies an EPS growth rate of 14.91% for this year and -3.75% for next year. EPS is expected to grow by 11.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -6.52%.
Float and Shares Shorts:
At present, 70.12 million ZYME shares are outstanding with a float of 67.09 million shares on hand for trading. On 2024-10-31, short shares totaled 4.7 million, which was 681.9999999999999 higher than short shares on 1727654400. In addition to Mr. Kenneth H. Galbraith C.A. as the firm’s Chairman of the Board, CEO & President, Dr. Paul A. Moore Ph.D. serves as its Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.98894 of ZYME’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ZYME reported revenue of $16000000.0 and operating income of -$34253000.0. The EBITDA in the recently reported quarter was -$31423000.0 and diluted EPS was -$0.39.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZYME since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZYME analysts setting a high price target of 28.0 and a low target of 12.0, the average target price over the next 12 months is 17.41111. Based on these targets, ZYME could surge 95.94% to reach the target high and fall by -16.03% to reach the target low. Reaching the average price target will result in a growth of 21.84% from current levels.
Analysts have provided yearly estimates in a range of -$0.66842 being high and -$2.06287 being low. For ZYME, this leads to a yearly average estimate of -$1.4636. The surprise factor in the prior quarter was -$0.31. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
